Most medullary thyroid carcinomas (MTC) recur or progress despite curative resection. Current targeted therapies show promise but lack durable efficacy and tolerability. The purpose of this study was to build on previous
in vitro work and evaluate withaferin A (WA), a novel RET inhibitor, in a metastatic murine model of MTC.
»
12/01/10